Stefani Spranger on β-Catenin Signaling and Overcoming Immunotherapy Resistance

Video

Stefani Spranger, PhD, University Chicago Melanoma Intrinsic β-Catenin Committee, discusses the effect of melanoma intrinsic β-catenin signaling on immune exclusion and resistance to immunotherapies.

Stefani Spranger, PhD, University Chicago Melanoma Intrinsic β-Catenin Committee, discusses the effect of melanoma intrinsic β-catenin signaling on immune exclusion and resistance to immunotherapies.

Melanoma intrinsic β-catenin, once its activated in melanoma, can mediate the exclusion of the immune system, says Spranger. Previous research has shown that t-cells can be used as predictive biomarker for the response rate of anti-PD-1 therapies.

When melanoma patients were segregated into those with a low t-cell gene signature and those with a high t-cell gene signature it was determined that the patients that did not have t-cells in their tumor microenvironment had β-catenin signaling, says Spranger.

Research on this topic is preliminary, says Sparnger, but once it is determined how the β-catenin pathway can be inhibited, it is possible to overcome resistance to immunotherapies.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD